Kamran Akhtar, MD
Infectious Disease · Louisville, KYNPI 1669486346
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,250 of the $4,359 with a category attached, or 74.6%. AbbVie accounts for 78.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $2,867 and has fallen 96.3% since, to $105 in 2024.
Across 53 payments — averaging $82.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Merck$233
- Smith+Nephew$184
- Shionogi Inc$172
- Tetraphase Pharmaceuticals, Inc.$86
- Melinta Therapeutics, LLC$68
- plus $179 from 8 others
What the payments were for
- Speaking & faculty fees$3,25075%
- Food & beverage$1,09625%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $3,437 |
| Merck | 18 | $233 |
| Smith+Nephew | 4 | $184 |
| Shionogi Inc | 8 | $172 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $86 |
| Melinta Therapeutics, LLC | 4 | $68 |
| Organogenesis Inc. | 3 | $43 |
| Boehringer Ingelheim | 1 | $24 |
| Pfizer | 1 | $23 |
| Medline Industries LP | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Bioventus LLC | 1 | $18 |
| Amgen | 1 | $18 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,359 in reported general payments places this provider in the 75th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 33 | $72,003 |
| Cefepime Hcl | 57 | $26,642 |
| Vancomycin Hcl | 112 | $23,991 |
| MicafunginMicafungin Sodium | 26 | $15,858 |
| CeftriaxoneCeftriaxone Sodium | 49 | $7,480 |
| Sodium Chloride0.9 % Sodium Chloride | 14 | $2,189 |
| Cefazolin Sodium | 12 | $870 |
| Doxycycline Hyclate | 22 | $149 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Louisville
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- Tariq MehmoodLouisville$75K
- Anupama RaghuramLouisville$9K
- Barbara WojdaLouisville$7K
- Benjamin KlausingLouisville$7K
- Forest ArnoldLouisville$4K
- Mark BurnsLouisville$3K
- Kenechukwu ObiokoyeLouisville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.